Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer
— ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile — Basel, December 14, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the publication of updated clinical data from the ongoing Phase I study of ANV419… Read more
01.11.2023
Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors
— ANV600 is a potent, cis-signaling, IL-2Rβ/γ agonist which efficiently expands intratumoral stem-like CD8+ T cells — Basel, November 1, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the 38th Annual Meeting… Read more
16.10.2023
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting
— ANV419 243 µg/kg selected as recommended Phase 2 dose for solid tumors — Basel, October 16, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the European Society of… Read more
03.06.2023
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
Basel, June 3, 2023 – OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma (download poster here). Read more
18.04.2023
Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting.
Basel, April 18, 2023 – Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting (download poster here). Read more
23.03.2023
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
— ANV600 is a potent, cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells — Basel, March 23, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for Cancer… Read more
02.02.2023
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
— OMNIA-1 is a Phase I/II study to determine the efficacy of ANV419 as monotherapy and in combination with anti-PD1 or anti-CTLA4 antibodies in advanced melanoma — Basel, February 2, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the first patient… Read more
30.11.2022
Anaveon appoints Dr Eduard Gasal as Chief Medical Officer
— An experienced CMO with a track record of multiple filings and drug approvals — Basel, November 30, 2022 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO). Dr Gasal will follow… Read more
10.11.2022
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
— ANV419 delivers high dose IL-2 to patients with good safety and tolerability — — Deepening of tumor response with continued ANV419 — Basel, November 10, 2022 – Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase… Read more
31.10.2022
Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
Basel, October 31, 2022 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston… Read more
10.09.2022
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
— ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity — — A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials, including in Multiple Myeloma, are in preparation… Read more
29.07.2022
Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022
Basel, July 29, 2022 – Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new preclinical data further elucidating the mode of action of this powerful and selective… Read more
13.07.2022
Anaveon appoints Dr Gary Phillips as Chief Business Officer
— Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions — Basel, July 13, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announces the appointment of Dr Gary Phillips as Chief Business… Read more
09.06.2022
Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419
Basel, June 9, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma.… Read more
08.04.2022
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
— ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity — — A Phase II program of ANV419 has been initiated in multiple tumor types, including melanoma, alongside multiple combination trials — Basel, April 8, 2022 – Anaveon,… Read more
09.03.2022
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022
Basel, March 9, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the… Read more
16.12.2021
Anaveon to raise CHF 110 million in oversubscribed Series B financing
— Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona — — Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple indications — Basel, December 16, 2021 – Anaveon, a clinical-stage immuno-oncology company, today announced that it has… Read more
12.11.2021
Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting
— ANV419 demonstrates highly promising safety profile — Basel, November 12, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting… Read more
24.06.2021
Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors
— ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer — Basel, June 24, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that it has successfully dosed the first patient in a Phase I/II open label study of ANV419,… Read more
25.03.2021
Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors
— ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer — Basel, March 25, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Clinical Trial Application (CTA) has been accepted by the Spanish Agency of Medicines and Medical… Read more
10.11.2020
Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
— ANV419 is a unique approach to no-alpha IL-2 agonists by taking advantage of a highly selective antibody which binds the same site as the alpha receptor and is able to completely abolish its binding — Basel, November 10, 2020 – Anaveon, an… Read more
10.04.2019
Anaveon announces appointment of Dr Allison Jeynes-Ellis to its Board of Directors
Basel, April 10, 2019 – Anaveon, an immuno-oncology company, today announced that it has appointed Dr Allison Jeynes-Ellis to its board of directors. Allison Jeynes-Ellis, MD, FFPM (UK), is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry.… Read more
26.02.2019
Anaveon, a new Immuno-Oncology company, announces CHF 35 million Series A financing
Basel, February 26, 2019 – Anaveon, an immuno-oncology company, today announced completion of a CHF 35 million Series A financing led by Syncona Ltd and joined by the Novartis Venture Fund. Martin Murphy and Dominic Schmidt from Syncona and Florian Muellershausen from Novartis Venture Fund… Read more
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy. Accept
